HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Primary myelodysplastic syndrome in Jordan: a single-centre experience.

AbstractOBJECTIVE:
Study of the disease patterns and clinical evaluation of myelodysplastic syndrome (MDS).
SUBJECTS AND METHODS:
A retrospective analysis was carried out on 85 patients, with MDS who were followed up over a period of 23 years at Jordan University Hospital, Amman, Jordan. Cases were analyzed according to the French, American and British Classification.
RESULTS:
Of the 85 patients, 42 (49.4%) were females and 43 (50%) males; mean age was 59 +/- 19 years (range 18-88). Most subtypes found in patients were refractory anemia (RA) in 27 (31.8%) and RA with excess blasts (RAEB) in 28 (32.9%). Adverse prognostic indicators were RAEB subtype and requirement for blood transfusion.
CONCLUSION:
Our findings showed that MDSs appeared at a younger age and tended to be of the aggressive subtype. Chronic myelomonocytic leukemia subtype seemed to appear dominantly in men.
AuthorsAbdalla Awidi, Ahmad Magableh, Ziad Taimeh, Hashim Ayyad, Nazzal Bsoul, Musleh Tarawneh
JournalMedical principles and practice : international journal of the Kuwait University, Health Science Centre (Med Princ Pract) Vol. 18 Issue 5 Pg. 351-5 ( 2009) ISSN: 1423-0151 [Electronic] Switzerland
PMID19648755 (Publication Type: Journal Article)
CopyrightCopyright 2009 S. Karger AG, Basel.
Topics
  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Anemia, Refractory, with Excess of Blasts (epidemiology, physiopathology)
  • Anemia, Sideroblastic (epidemiology, physiopathology)
  • Developing Countries
  • Disease Progression
  • Female
  • Hospitals, University
  • Humans
  • Jordan (epidemiology)
  • Kaplan-Meier Estimate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (epidemiology, physiopathology)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Sex Distribution
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: